EY: Don’t Expect Mega-Mergers To Return, But ‘Never Say Never’
EY Predicts Continued Emphasis On Bolt-On Deals, Partnerships In 2022
Executive Summary
Firm’s annual biopharma firepower report notes there were no mega-mergers in 2021 and the conditions continue to make smaller deals and partnerships a better risk proposition.
You may also be interested in...
Biopharma Has Money To Spend On M&A, EY Says – As Well As Need
Upcoming patent expirations are increasing the sector’s need to acquire candidates and products that can deliver near-term revenues, driving up valuations, EY’s 2024 Firepower report says.
M&A Has Been Down, But EY Argues Conditions Are Right For An Uptick In 2023
Despite concerns about the impact of the Inflation Reduction Act and constraining factors like inflation, EY believes more than $1.4tn in life sciences industry “firepower” should result in increased deal-making this year.
Are Market Conditions Setting Up A Biopharma M&A Wave?
A new EY report contends that declining biotech valuations and the need for large pharma to add pipeline assets may create conditions for a buyer’s market – although year-to-date M&A activity has been lackluster.